ArticleNeurochemical research2026
Lycium Barbarum Polysaccharides Alleviate Parkinson's Disease-Induced Neurodegeneration by Up-Regulating USP10 to Modulate Endoplasmic Reticulum Stress.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Endoplasmic reticulum stress (ERS) is a significant pathological mechanism in Parkinson's disease (PD), and prolonged ERS can ultimately lead to cellular apoptosis. This study aimed to investigate the neuroprotective effects of Lycium barbarum polysaccharides (LBP) against MPP⁺-induced damage in primary neurons. Mouse primary dopaminergic neurons were treated with MPP⁺ for 24 h to establish PD cell model, and then treated with LBP for another 24 h. Western blot analysis revealed that, compared to the Control group, MPP⁺ treatment induced primary neuron ERS and apoptosis, manifested by upregulating the expression of ERS and apoptotic marker proteins GRP78, p-IRE1α, p-eIF2α, ATF-4, CHOP, Caspase-3 and Bax, repressing mitochondrial transmembrane potential and promoting ROS production, and LBP treatment significantly counteracted MPP
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.